SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (2892)12/22/2004 1:41:50 PM
From: Walkingshadow  Read Replies (1) | Respond to of 8752
 
Ah.... very nice.

It gapped up today as I guessed it might.

Next stop: $2.75?

ISLE seems to be moving now also:

139.142.147.218

T



To: Vendit™ who wrote (2892)12/22/2004 1:57:29 PM
From: Carolyn  Read Replies (1) | Respond to of 8752
 
Yes, but doesn't it look toppy right now?



To: Vendit™ who wrote (2892)12/22/2004 1:57:51 PM
From: Walkingshadow  Read Replies (1) | Respond to of 8752
 
Another one like UGNE. This is YMI:

139.142.147.218

Is it "deja vu all over again?"

<gg>

This one is in a very hot sector, the new cancer treatments and vaccines stocks. Good news on YMI today also, and according to Merriman, YMI is undervalued relative to its peers:

=====================================================

Merriman notes that yesterday YMI announced preliminary results from a randomized phase II trial conducted by its licensor in Cuba, and says TheraCIM may be better than equivalent to Erbitux. Notably, there was no evidence of skin rash, which has been seen with all other EGF receptor-blocking agents and has previously been assumed to be inseparable from efficacy. While survival data will be needed in order to compare these impressive tumor response results with those of Erbitux radiation therapy in head and neck cancer, firm believes that increasing visibility of the co's valuable pipeline could catalyze gains in the stock over the next 12-18 months toward $8-$12, a valuation more closely in-line with peers.

T



To: Vendit™ who wrote (2892)12/22/2004 2:48:51 PM
From: Vendit™  Respond to of 8752
 
I'm going to stay in until the appearance of the first black candlestick at close. (exit just prior to close) or a sudden intra-day drop.

139.142.147.218


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News